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Development of a vaccine to protect against cryptococcosis is a priority
given the enormous global burden of disease in at-risk individuals. Using glucan particles (GPs) as a delivery system, we previously demonstrated that mice vaccinated
with crude Cryptococcus-derived alkaline extracts were protected against lethal challenge with Cryptococcus neoformans and Cryptococcus gattii. The goal of the present
study was to identify protective protein antigens that could be used in a subunit
vaccine. Using biased and unbiased approaches, six candidate antigens (Cda1, Cda2,
Cda3, Fpd1, MP88, and Sod1) were selected, recombinantly expressed in Escherichia
coli, puriﬁed, and loaded into GPs. Three mouse strains (C57BL/6, BALB/c, and DR4)
were then vaccinated with the antigen-laden GPs, following which they received a
pulmonary challenge with virulent C. neoformans and C. gattii strains. Four candidate
vaccines (GP-Cda1, GP-Cda2, GP-Cda3, and GP-Sod1) afforded a signiﬁcant survival
advantage in at least one mouse model; some vaccine combinations provided
added protection over that seen with either antigen alone. Vaccine-mediated protection against C. neoformans did not necessarily predict protection against C. gattii.
Vaccinated mice developed pulmonary inﬂammatory responses that effectively contained the infection; many surviving mice developed sterilizing immunity. Predicted
T helper cell epitopes differed between mouse strains and in the degree to which
they matched epitopes predicted in humans. Thus, we have discovered cryptococcal
proteins that make promising candidate vaccine antigens. Protection varied depending on the mouse strain and cryptococcal species, suggesting that a successful human subunit vaccine will need to contain multiple antigens, including ones that are
species speciﬁc.

ABSTRACT

The encapsulated fungi Cryptococcus neoformans and Cryptococcus
gattii are responsible for nearly 200,000 deaths annually, mostly in immunocompromised individuals. An effective vaccine could substantially reduce the burden of
cryptococcosis. However, a major gap in cryptococcal vaccine development has
been the discovery of protective antigens to use in vaccines. Here, six cryptococcal
proteins with potential as vaccine antigens were expressed recombinantly and puriﬁed. Mice were then vaccinated with glucan particle preparations containing each
antigen. Of the six candidate vaccines, four protected mice from a lethal cryptococcal challenge. However, the degree of protection varied as a function of mouse
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strain and cryptococcal species. These preclinical studies identify cryptococcal proteins that could serve as candidate vaccine antigens and provide a proof of principle
regarding the feasibility of protein antigen-based vaccines to protect against cryptococcosis.
KEYWORDS Cryptococcus, bioinformatics, glucans, immunization, major
histocompatibility complex

T

he encapsulated yeasts Cryptococcus neoformans and Cryptococcus gattii are major
causes of morbidity and mortality in persons with qualitative and quantitative
impairment of CD4⫹ T cells (1, 2). Worldwide, it has been estimated that close to
200,000 people with AIDS die from cryptococcal meningitis annually (3). The lifetime
incidence of cryptococcosis in recipients of solid organ transplants is approximately 3%
(4). Other high-risk groups have been identiﬁed, including persons with lymphoma,
sarcoidosis, and idiopathic CD4 lymphocytopenia. C. gattii is more of a primary pathogen than C. neoformans, with many cases occurring in individuals with relatively intact
immune function (1, 2). Of particular concern is the emergence and spread of hypervirulent C. gattii strains in parts of Canada and the United States (2, 5, 6).
Exposure to Cryptococcus is thought to most commonly occur following inhalation
of fungi into the lungs (1, 7). If innate defenses fail, then an adaptive antigen-speciﬁc,
T cell-mediated immune response becomes critical for preventing local spread and
dissemination. Antibody responses, particularly those directed against glucuronoxylomannan (GXM) and other polysaccharide components in the capsule, appear to contribute to the adaptive response in at least some individuals (8).
The high global burden of cryptococcosis (3) has prompted research into the
development of vaccines to protect individuals at high risk. Protection of mice using
live and killed vaccines has been demonstrated using genetically altered whole yeast
cells (9–12). Vaccines comprised of GXM and other cell wall carbohydrates conjugated
to carrier proteins elicit antibody responses to GXM that protect in experimental
models of cryptococcosis (13, 14). We and others have focused on the discovery of
C. neoformans antigens that stimulate T cell responses and thus could serve as
candidate antigens in cryptococcal vaccines (15–18). Moreover, because most vaccine
adjuvants presently in clinical use stimulate predominantly protective antibody responses (19), we postulate that a successful vaccine will need to incorporate adjuvants
and/or delivery systems that elicit strong T cell responses.
Our laboratories have been exploring glucan particles (GPs) as a combined
delivery system and adjuvant for cryptococcal vaccines. GPs are hollow, porous
yeast cell wall shells produced by treating Saccharomyces cerevisiae with a series of
alkaline, acid, and solvent extractions (20–23). They are principally composed of
␤-1,3-glucan polymers with about 2% chitin and undetectable amounts of proteins,
lipids, and mannans. Immune recognition of GPs is mediated by Dectin-1 and
complement receptors (24). Immunization of mice with GPs containing trapped
ovalbumin results in robust and durable antigen-speciﬁc antibody and Th1/Th17biased CD4⫹ T cell responses (20, 21).
Recently, we performed whole-cell mild alkali extraction of acapsular mutant strains
of C. neoformans and C. gattii. The soluble extracts were loaded into GPs and used to
vaccinate mice. Mice so vaccinated exhibited CD4⫹ T cell recall responses in the lungs
and were partially protected from pulmonary challenge with C. neoformans and C. gattii
(15). In the present study, we sought to identify speciﬁc cryptococcal proteins responsible for protection. Candidate antigens were chosen using biased and unbiased
approaches, recombinantly expressed in Escherichia coli, and loaded into GPs. Mouse
strains were vaccinated with the antigen-laden GPs and then challenged with C. neoformans and C. gattii. We found that protection varied depending on the antigen,
mouse strain, and cryptococcal species.
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TABLE 1 Recombinant proteins of C. neoformans strain H99 expressed in E. coli and used for testing as vaccines

CNAG no.
CNAG_05799
CNAG_01230
CNAG_01239
CNAG_06291
CNAG_01019
CNAG_00776

Name
Cda1
Cda2
Cda3
Fpd1
Sod1
MP88

Description
Chitin deacetylase
Chitin deacetylase
Chitin deacetylase
Polysaccharide deacetylase
Superoxide dismutase
Mannoprotein

Region
expressed
20–374
20–378
19–336
20–249
2–154
23–294

Vector
pET200
pET200
pET19b
pET200
pET200
pET200

Expressed
protein mass
(kDa)
42.3
43.8
37.9
29.3
20.1
32.9

% of identity to
C. gattii R265
homologa
90
88
87
92
70
94

Human
homologyb
None
None
5.3
None
5⫺62
None

No. of
RNA-seq
readsc
139,907
5,835
864
1,511
70,771
24,244

aC.

gattii strain R265 protein sequences were retrieved from the Ensembl Fungi website (http://fungi.ensembl.org/index.html). Regions of C. gattii protein comparable
to C. neoformans protein sequence expressed in E. coli were aligned to calculate the percentage of identity.
bHomology to the human protein with the highest similarity (BLASTp analysis); the smaller the numerical value, the greater the similarity.
cShown are the average numbers of normalized RNA-seq reads recorded for two strains of Cryptococcus isolated directly from infected human patients (GEO GenBank
accession no. GSE51573) (28).

MP88

Cda3

Cda2

Cda1

Fpd1

Sod1

RESULTS
The six cryptococcal proteins selected for testing are described in Table 1. The
immunogenic properties of three of the proteins (Cda2, Fpd1, and MP88) have previously been reported (16–18). Cda1 and Cda3 were chosen as they are chitin deacetylases (Cda) with protein sequence homology to Cda2 (25) and for the importance of
Cda proteins for virulence (26). Sod1 was the most abundant protein in a mild alkaline
extract that was immunoprotective (15) and contributes to virulence of C. gattii (27).
With the exception of Sod1, the six proteins have little to no homology to human
proteins. RNA encoding each of the proteins has been identiﬁed by transcriptome
sequencing (RNA-seq) in C. neoformans obtained from human patients with cryptococcal meningitis (28). In addition, all six proteins have been identiﬁed as part of the
secretome of the fungus (29, 30). The C. neoformans strain H99 proteins were expressed
with a His tag in E. coli (Table 1) and puriﬁed over a nickel column. Five of the
recombinant proteins were made from cDNA generated from isolated mRNA, while the
cDNA for Cda3 expression was synthesized. Sequences for a predicted signal peptide
(found in the full-length proteins, except for Sod1), as well as C-terminal serine/
threonine-rich regions and a putative glycosylphosphatidylinositol (GPI) anchor motif
(found in the proteins except Fpd1 and Sod1) were not included. Milligram quantities
of each protein were puriﬁed, conﬁrmed to be of the correct size by SDS-PAGE (Fig. 1),
and loaded into GPs, typically at 10 g per vaccine dose.
The vaccines were ﬁrst tested in C57BL/6 mice. Each mouse received a prime and
two boosts of GPs formulated with either one of the six recombinant proteins or with
mouse serum albumin (MSA) as a control. Two weeks following the last boost, the mice

250 150 100 75 50 37 25 20 15 10 -

FIG 1 SDS-PAGE of puriﬁed recombinant proteins used to make GP vaccines. Each lane contains 10 g
of total protein. Proteins were stained with Coomassie. Molecular masses (in kilodaltons) of protein
standards are indicated. The expected molecular masses of the proteins are listed in Table 1.
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FIG 2 Vaccination studies with GP-recombinant protein vaccines in C57BL/6 mice. Mice were vaccinated 3 times with 10
g/vaccine dose of the indicated recombinant protein in GPs and then challenged with 104 CFU of strain KN99. Survival curves
and fungal burden in the lungs of mice that survived 84 days p.i. are shown for mice vaccinated with one recombinant protein
(A and B) and with two recombinant proteins (C and D). Data were combined from two to three independent vaccination
studies with ﬁve to six mice per vaccination group in each study. (A) P ⬍ 0.001 comparing MSA with Sod1, Cda1, or Cda2. (C)
P ⬍ 0.001 comparing MSA with any other group. In panels B and D, the dotted line indicates the CFU of KN99 challenge;
median CFU per lung for each group are indicated by a solid line.

were challenged with C. neoformans strain KN99 and monitored for 84 days. Signiﬁcantly prolonged survival was observed following vaccination with Sod1, Cda1, and
Cda2 (Fig. 2A). Some of the survivors had undetectable lung CFU when the study was
terminated (Fig. 2B). Binary combinations of Sod1, Cda1, and Cda2 in GPs were then
tested, with Cda1/Cda2 showing the most promising results (Fig. 2C and D). When the
vaccine candidates were tested in BALB/c mice, complete and nearly complete protection was observed with Cda2 and Cda1, respectively (Fig. 3). Partial protection was
again seen with Sod1. Cda3, which did not protect C57BL/6 mice, partially protected
the BALB/c mice.
Next, we assessed the capacity of Cda1, Cda2, and Cda3 GP-based vaccines to
protect following challenge with C. gattii strain R265. For C57BL/6 mice, the survival
curves were nearly identical comparing lethal infections with C. neoformans to that with
C. gattii; Cda1 and Cda2 were protective against both strains, whereas Cda3 was not
(Fig. 4A). However, at the termination of the study, lung fungal loads and weights were
signiﬁcantly lower in the Cda1-vaccinated mice challenged with KN99 compared with
R265 (Fig. 4B). In contrast to C57BL/6 mice, BALB/c mice challenged with R265 had only
a minor prolongation of survival following vaccination with GPs containing Cda1, Cda2,
or Cda3 (Fig. 4C). Moreover, BALB/c mice vaccinated with both GP-Cda1 and GP-Cda2
(Cda1/Cda2) and challenged with R265 all succumbed by day 52 postinfection (p.i.) (see
Fig. S1 in the supplemental material).
In the next set of experiments, we examined pulmonary fungal loads following
November/December 2017 Volume 8 Issue 6 e01872-17
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FIG 3 Vaccination studies with GP-recombinant protein vaccines in BALB/c mice challenged with KN99. Studies were conducted as in Fig. 2A and B, except
BALB/c mice were used, and the comparator was unvaccinated (UnVac) mice. Survival curves and fungal burden in the lungs of mice that survived 84 days p.i.
are shown. Data were combined from two to three independent vaccination studies with four to ﬁve mice per vaccination group in each study. P ⬍ 0.001
comparing UnVac with Sod1, Cda1, Cda2, or Cda3. For panel B, the dotted line identiﬁes CFU of KN99 challenge; median CFU per lung for each group are
indicated by a solid line.

challenge of GP-Cda1/Cda2-vaccinated C57BL/6 and BALB/c mice with 104 CFU of
C. neoformans KN99. Control mice were immunized with GP-MSA. Mice were euthanized at selected time points. For both strains of mice immunized with GP-MSA, lung
CFU rose inexorably (Fig. 5). Levels close to 109 CFU/lung were seen 21 days after
challenge, a time point shortly before the mice typically succumb to infection. In
contrast, for mice vaccinated with GP-Cda1/Cda2, lung CFU initially rose, but then
eventually declined in the day 84 survivors. However, the mouse strains differed at the
intermediate time points studied, with the C57BL/6 mice showing highly variable
numbers of CFU, whereas the BALB/c mice had a steady, consistent decline 7 days after
challenge.
Lung sections were prepared from BALB/c mice vaccinated with GP-Cda1/Cda2 or
GP-MSA 7 and 14 days after challenge with KN99 and evaluated for fungal burden and
extent of inﬂammation by a pathologist blind to experimental condition (Fig. 6A; see
Fig. S2 in the supplemental material). Hematoxylin and eosin (H&E)-stained sections
revealed mixed inﬂammatory inﬁltrates predominantly composed of histiocytes and
small numbers of neutrophils and eosinophils within the airways, adjacent alveolar
spaces, and walls in all the groups (Fig. 6A). Aggregates of lymphocytes consistent with
the formation of inducible bronchus-associated lymphoid tissue (iBALT) were also
noted in some of the airway walls in all groups, including the GP-MSA controls. The
inﬂammation progressed to involve more distant airspaces and walls (in addition to
airways and adjacent alveolar airspaces and walls) in mice sacriﬁced at day 14 compared to those sacriﬁced at day 7. In addition, we noted a slight increase in the
proportion of neutrophils among the inﬂammatory inﬁltrates at day 14. When comparing the lung pathology at day 7 of mice vaccinated with GP-Cda1/Cda2 to that of
controls that received GP-MSA, there was a trend toward greater inﬂammation in the
vaccinated group, suggesting the vaccine promoted an earlier and more intense
immune response to fungal microorganisms. No signiﬁcant, morphological differences
were noted in the extent of the inﬂammation in different mouse groups sacriﬁced at
day 14 (Fig. S2). Mucicarmine-stained sections highlighted that yeast cells present
within the airways and airspaces were surrounded by inﬂammatory cells (Fig. 6).
Consistent with the quantitative CFU data, we noted signiﬁcantly fewer microorganisms
in mice vaccinated with GP-Cda1/Cda2 compared with controls that received GP-MSA
on both days 7 and 14.
November/December 2017 Volume 8 Issue 6 e01872-17
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FIG 4 Survival of vaccinated C57BL/6 and BALB/c mice following infection with C. gattii strain R265. C57BL/6 (A) and BALB/c (C) mice were
vaccinated 3 times with 10 g/vaccine dose of recombinant Cda1, Cda2, or Cda3 in GPs. Control mice were left unvaccinated (UnVac). Mice were
then challenged with 104 CFU of KN99 (C. neoformans) or R265 (C. gattii). Panel B shows fungal burden in the lungs (left panel) and lung weights
(right panel) of C57BL/6 mice vaccinated with GP-Cda1 that survived 84 days. Data were combined from two to four independent experiments,
each with four to ﬁve mice per group. (A) P ⬍ 0.001 comparing UnVac with Cda1 or Cda2 for both KN99 and R265. (B) P ⬍ 0.01 and P ⬍ 0.001
comparing fungal load and lung weight, respectively, in KN99 with R265. (C) P ⬍ 0.05 comparing UnVac with any other group. In panel B, the
dotted line indicates CFU of KN99 challenge; the median CFU per lung for each group are indicated by a solid line.

Lung sections from mice vaccinated with GP-Cda1/Cda2 and euthanized at day 84
post-cryptococcal challenge revealed scattered aggregates of lymphocytes in the wall
of the airways (iBALT) (Fig. 6B). Rare collections of alveolar macrophages with foamy
cytoplasm were also noted in lung sections. However, no fungal microorganisms were
identiﬁed on H&E- and mucicarmine-stained sections. There were no surviving control
GP-MSA mice at day 84 to study comparatively.
We next assessed whether the lead vaccine candidates could protect translationally
relevant humanized DR4 mice against challenge with C. neoformans strain KN99. DR4
mice have a C57BL/6 background, but express human major histocompatibility complex class II (MHC-II) HLA-DR4 (DRB1*0401) while lacking endogenous murine MHC-II
(31). GPs containing Cda1 or the combination of Cda1 and Cda2 induced protective
responses in DR4 mice that were comparable to that seen following vaccination of
C57BL/6 mice (Fig. 7). However, vaccines containing Cda2 and Sod1, which signiﬁcantly
protected C57BL/6 mice, afforded the DR4 mice no protection.
Finally, we performed individual epitope mapping of the six proteins of interest to
try to understand the mechanisms responsible for the observed differences in vaccine
responses among mouse strains and to assess the potential of the proteins as candidate
antigens in human vaccines (see Fig. S3 in the supplemental material). Each protein
contains several high-probability B cell linear epitopes and from 1 to 3 sequences
comprising strong MHC-II binding for multiple human and murine alleles. In Fig. S3A to
November/December 2017 Volume 8 Issue 6 e01872-17
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FIG 5 Lung CFU of C57BL/6 and BALB/c mice vaccinated with GP-Cda1/Cda2 and challenged with C. neoformans strain KN99. C57BL/6 (A) and BALB/c (B) mice
were vaccinated three times with 10 g/vaccine dose of GP-Cda1 and GP-Cda2 (GP-Cda1/Cda2) and then challenged with 104 CFU of C. neoformans strain KN99.
Control mice received GP-MSA. At the indicated time points, mice were euthanized and lung CFU determined. For panel A, GP-Cda1/Cda2 data were collected
from three independent studies (does not include day 84 data from Fig. 2D), and for panel B, data were from two independent studies. Each datum point
represents the CFU from one mouse.

F, high-probability B cell epitopes and predicted MHC-II high-binding peptides are
indicated with a score exceeding 1 standard deviation from the mean for that protein.
Within these regions, multiple peptides are also predicted to be excised by cathepsin
B, L, or S (data not shown) and so have the potential for presentation as T cell epitopes
by antigen-presenting cells. When examined from the perspective of individual murine
MHC-II allele binding, there are differences in the predicted binding between alleles,
leading to differences in epitope dominance between mice. For instance, in Cda1,
Fig. S3A shows similarity between binding by H2-I-Ab (C57BL/6) and H2-I-Ad (BALB/c)
for the 15-mer with its index position at position 309, but similarity between H2-I-Ad
and the human DRB1:0401 is carried by the DR4 mouse at positions 291 to 292. This
may result in the observed differences in survival between C57BL/6, BALB/c, and DR4
mice. Thus, all of the recombinant proteins are characterized as good potential immunogens that are likely to elicit antibody responses and sustained cellular recall
responses. The engineering in of the N-terminal His tag did not apparently bias the
potential immunogenicity or dominance of the epitopes of the Cryptococcus protein.
DISCUSSION
Compared with vaccines featuring whole organisms or crude antigen preparations,
subunit vaccines have the advantage of being well deﬁned and less likely to elicit
adverse reactions, including autoimmune responses. Here, we identify several antigens
that, when used as part of a GP-based vaccine formulation, protect mice against lethal
cryptococcal challenge. Cda2 (also known as MP98) was originally identiﬁed as the
antigen that stimulated a T cell hybridoma generated from immunized mice (16).
Subsequent studies using a peptide–MHC-II tetramer containing a 13-amino-acid peptide from Cda2 revealed that 6.5% of Th cells stained with the tetramer 14 days
postinfection with C. neoformans strain KN99 (32). In addition to being identiﬁed on our
biased screen of immunostimulatory proteins, Cda2 was the ﬁfth most common protein
found in the protective alkaline extracts (15). The two other deﬁnitive Cdas, Cda1 and
November/December 2017 Volume 8 Issue 6 e01872-17
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GP-MSA; Day 7 PI

GP-Cda1,2; Day 7 PI

20x
H&E

B

GP-Cda1,2; Day 84 PI

20x

100x
H&E
100x

400x
H&E
400x

200x
Mucicarmine

FIG 6 Histology of mouse lungs. Shown are representative H&E- and mucicarmine-stained sections of lungs from vaccinated mice. (A) Mice were vaccinated
three times with 10 g/vaccine dose of GP-Cda1 and GP-Cda2 (GP-Cda1/Cda2) and then challenged with 104 CFU of C. neoformans strain KN99. Control mice
received GP-MSA. After 7 (A) and 84 (B) days, mice were euthanized and lung sections prepared. Scale bars on the photomicrographs are as follows: 20⫻ ⫽
1 mm, 100⫻ ⫽ 100 m, 200⫻ ⫽ 50 m, and 400⫻ ⫽ 20 m.

Cda3, were also tested in our vaccine model. Each of the three recombinant CDAs,
when delivered in a GP-based vaccine, protected at least one mouse strain against
C. neoformans challenge, with rCda1 and rCda2 being the most promising of the
antigens. Interestingly, it was recently shown that vaccination with a strain of C. neoformans genetically deﬁcient in CDAs protected mice against a subsequent lethal
C. neoformans challenge (9). Taken together, these data highlight that while the CDAs
are promising vaccine candidates, other protective antigens exist.
One such protective antigen, identiﬁed as one of the top two hits in our unbiased
screen (15), is Sod1. These results validate the unbiased approach, and we are presently
testing the other abundant proteins identiﬁed in the alkaline extracts. While the CDAs
have little to no homology with human proteins, Sod1 may not be an ideal candidate
vaccine antigen due to its signiﬁcant homology with human superoxide dismutase
(SOD). However, the immunoinformatic analysis supports the prospect that epitope
mapping will identify a protective region within the antigen that has minimal homolNovember/December 2017 Volume 8 Issue 6 e01872-17
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FIG 7 Protection of vaccinated DR4 mice from infection with C. neoformans strain KN99. DR4 and wild-type (WT)
C57BL/6 mice were vaccinated three times with 10 g/vaccine dose of GPs containing (A) Cda1, (B) Cda2, (C) Cda1
and Cda2 (Cda1/Cda2), and (D) Sod1. Control mice received GPs containing MSA or were left unvaccinated (UnVac).
Mice were then challenged with 104 CFU of C. neoformans strain KN99 and monitored for survival. Data from
vaccinated DR4 mice were combined from at least two independent experiments with a total of 10 to 20 mice per
vaccination group. The number of control mice per experimental group ranged from 5 to 10. P ⬍ 0.001 comparing
DR4 MSA with DR4 Cda1, P ⬍ 0.05 comparing DR4 MSA with DR4 Cda2, and P ⬍ 0.001 comparing DR4 UnVac with
DR4 Cda1/2.

ogy with human antigens. Indeed, future studies will seek to ﬁnd such regions within
the various protective antigens and then test the efﬁcacy of chimeric antigens containing the protective epitopes.
The recombinant proteins were made in E. coli and thus are likely lacking in
glycosylation. Cryptococcal N-linked and O-linked glycans generally are terminally
mannosylated. Upon infection, the mannose groups are recognized by C-type lectin
receptors with afﬁnity for mannose (22). Notably, this interaction of mannosylated
proteins with host mannose receptors augments immunity. Diminution of T cell
responses was observed following chemical deglycosylation of cryptococcal mannoproteins or by blocking mannose receptors with mannan (33, 34). In addition, Cda2speciﬁc cytokine production was greater when cells were stimulated with recombinant
Cda2 (rCda2) produced in the yeast Pichia pastoris, compared with E. coli-derived
protein (35). Nevertheless, in the present study, the mice were protected following
vaccination with proteins made in E. coli. We posit this is because the antigens are
encased in GPs that are phagocytosed by Dectin-1 and complement receptors (24),
obviating the participation of mannose receptors. Nevertheless, it would be interesting
to compare responses of native and unglycosylated cryptococcal antigens encased
in GPs.
A challenge in the development of vaccines designed to stimulate T cell-mediated
protection is the diversity of MHC alleles within the human population (19). We tested
our GP-based vaccines using three different mouse strains: C57BL/6, BALB/c, and DR4.
We found that for a given antigen, the degree of observed protection varied as a
November/December 2017 Volume 8 Issue 6 e01872-17
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function of mouse strain. The importance of MHC-II is evident comparing C57BL/6 and
DR4 mice; GP-Cda2 and GP-Sod1 were partially protective vaccines in C57BL/6, but
not DR4 mice. These mice share genetic backgrounds, with the exception that in
transgenic DR4 mice, native MHC class II molecules have been replaced by human
HLA-DR4 (36). GP-Cda1 and GP-Cda2 vaccines afforded complete or nearly complete
protection in BALB/c mice, with many of the mice having undetectable CFU in the lungs
at the time of euthanasia. Moreover, the GP-Cda3 vaccine, which was not protective in
C57BL/6 and DR4 mice, was partially protective in BALB/c mice. As shown in Fig. S3, the
predicted MHC-II binding afﬁnity of individual sequential peptides within each protein
varies considerably between the MHC-II alleles of BALB/c and C57BL/6 and DR4. Similar
differences may be expected between individual human MHC-II alleles; the permuted
average of the predicted binding of each peptide across multiple human MHC-II alleles
provides an indication (Fig. S3) of which mouse epitopes may be most likely to elicit a
comparable result in the human population. However, taken together, these results
suggest that a successful cryptococcal vaccine that stimulates T cell protective responses in humans will require a combination of antigens or epitopes.
Pathology and CFU data demonstrate that vaccinated mice are able to mount an
inﬂammatory response during the ﬁrst week of infection and that this inﬂammatory
response is correlated with a reduction in the fungal burden compared with challenged
mice that received control vaccine. At day 7, vaccinated mice had 3- to 8-fold fewer CFU
in the lung than control mice. By 14 days postinfection, the inﬂammatory responses in
control and vaccinated mice are similar, yet CFU continue to rise in control mice while
plateauing or falling in the vaccinated animals. This suggests there are differences in
the qualitative nature of the inﬂammatory response not detected on H&E staining. We
have shown that GP-based vaccines promote robust antigen-speciﬁc antibody, Th1,
and Th17 responses (15, 20, 21). Importantly, Th1 and Th17 recall responses to the lungs
occur following pulmonary challenge of vaccinated mice (15). Ongoing work is directed
at further deﬁning the mechanisms responsible for the protection observed with the
GP-based recombinant protein vaccines.
It is estimated that C. neoformans and C. gattii diverged between 16 and 160
million years ago (37). Both species share major virulence determinants, although a
comparison of their genomes reveals only 86% identity (37–39). Differences in immunopathology have been noted in experimental murine models when comparing infections with the two species (38, 40, 41). Thus, it was of interest to see whether vaccines
that protected against C. neoformans would provide cross-protection in C. gattii models
of infection. Remarkably, we found vaccination with GP-Cda1 and GP-Cda2 provided
almost identical levels of protection against both cryptococcal species in C57BL/6 mice.
However, in BALB/c mice, the same vaccines provided robust protection against
challenge with C. neoformans but no protection against C. gattii. Comparative epitope
mapping of C. neoformans and C. gattii is under way to determine if differences in
epitopes engendered by the 35- to 42-amino-acid differences in each protein assist in
identifying the basis for protection. The cryptococcal strains we used, KN99 and R265,
are hypervirulent and thus provide a stringent test for any vaccine; future studies also
will examine epitope differences in additional cryptococcal strains that commonly
cause disease in humans.
Using the model antigen ovalbumin encapsulated in GPs, we previously demonstrated robust CD4⫹ T cell and antibody responses occur even after immunization with
submicrogram doses of antigen (21). Our new studies extend these ﬁndings to demonstrate the utility of using the GP-based delivery system as an effective tool for vaccine
antigen discovery. Four of the six antigens tested, when administered as a GP-based
vaccine, provided signiﬁcant protection in at least one mouse model. We are currently
using this approach to identify other protective antigens based on our biased and
unbiased screens. Eventually, the antigens must be tested in human systems. Moreover,
as the greatest risk factor for cryptococcosis is T cell dysfunction (7), we hypothesize
that a successful cryptococcal vaccine for use in humans will need to elicit not only T
cell responses to protein antigens but also antibody responses. Regarding the latter,
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antibody to capsular and cell wall carbohydrates has been shown to be protective in
some models of cryptococcosis (13, 14, 42). Using the GP delivery system, we are
currently testing whether the addition of GXM conjugated to a protein carrier will boost
protection in mouse models.
MATERIALS AND METHODS
Chemicals and culture media. Chemical reagents were from Thermo Fisher Scientiﬁc (Pittsburgh,
PA), unless stated otherwise. The media used for culturing of Cryptococcus were YPD (Difco yeast extract,
Bacto peptone, dextrose, with and without 2% agar) and Sabouraud dextrose agar Emmons (Remel).
E. coli strains TOP10 and BL21 were cultured at 37°C in LB broth or agar. Transformed strains of BL21 were
used for protein expression by being cultured for 18 h at 30°C with shaking in Overnight Express Instant
TB medium (EMD Millipore, Billerica, MA). Antibiotic selection was with ampicillin (100 g/ml) or
kanamycin (100 g/ml).
Strains of Cryptococcus. C. neoformans var. grubii strains KN99 (43) and cap59 (44) and C. gattii strain
R265 (45) were maintained as glycerol stocks at ⫺80°C and initially cultured on YPD agar. To prepare
Cryptococcus for in vivo challenge studies, KN99 and R265 were cultured in liquid YPD for 15 to 22 h at
30°C with shaking. Yeast cells were then harvested by centrifugation, washed once with phosphatebuffered saline (PBS), counted using a hemocytometer, and ﬁnally suspended in PBS at 2 ⫻ 105 cells/ml.
CFU were determined on Sabouraud dextrose agar.
Expression of cryptococcal proteins in E. coli. Six C. neoformans strain H99 proteins were expressed
in E. coli (Table 1) for subsequent testing as vaccine candidates. When present, cDNA was deleted of
regions coding for a signal peptide and C terminus rich in serine and threonine and the GPI anchoring
motif. Five proteins were expressed following cloning of PCR-ampliﬁed cDNA in pET200/D-TOPO
(Invitrogen), and for the sixth protein its cDNA was synthesized and cloned in pET19b by GenScript
(Piscataway, NJ). Both vectors are designed to fuse vector-encoded sequence that contains a His tag to
the N terminus of the cloned cDNA.
Brieﬂy, strain cap59 was cultured in YPD at 30°C with shaking to the mid-log phase. Approximately
108 cells were collected by centrifugation in a 2.0-ml microcentrifuge tube, suspended in 0.7 ml RLT Plus
buffer containing ␤-mercaptoethanol, and homogenized using 0.6 ml of 0.7-mm zirconium beads
(BioSpec Products, Bartlesville, OK). Puriﬁcation of RNA from the homogenate was performed according
to the manufacturer’s instructions (RNeasy Plus minikit; Qiagen, Hilden, Germany). Puriﬁed RNA was used
to make cDNA using the iScript cDNA synthesis kit (Bio-Rad Laboratories, Hercules, CA). The cDNA was
then used as the template for ampliﬁcation by PCR with Platinum Pfx DNA polymerase (Invitrogen) with
gene-speciﬁc primers designed for directional cloning. Each PCR product was puriﬁed using a QIAquick
PCR puriﬁcation kit (Qiagen) and then ligated to pET200/D-TOPO according to the manufacturer’s
instructions that accompanied the Champion pET 200 Directional TOPO expression kit (Invitrogen). The
ligated DNA was transformed into E. coli TOP10 cells and plated for single-colony isolation. Several
colonies were screened by PCR using PCR SuperMix (Invitrogen) and gene-speciﬁc primers. PCR products
of the predicted size following electrophoresis in agarose were conﬁrmed, and plasmid DNA was puriﬁed
from select clones grown in 4 ml LB-kanamycin medium using a QIAprep spin miniprep kit (Qiagen). DNA
then was sequenced (GeneWiz, South Plainﬁeld, NJ) using vector forward and reverse primers. Plasmids
conﬁrmed to have the expected cDNA sequence ligated correctly were transformed into E. coli BL21 cells
for protein expression. Glycerol stocks of E. coli were made for storage at ⫺80°C.
Puriﬁcation of proteins. Each recombinant BL21 strain was grown in 50 ml of Overnight Express
medium with antibiotic in 250-ml bafﬂed culture ﬂasks (Bellco Glass, Vineland, NJ) at 30°C for 18 h.
Cultures were inoculated with approximately 25 l of ⫺80°C glycerol stock. The buffers used in
puriﬁcation of protein on His·Bind resin were recommended by the manufacturer (EMD Millipore). Cells
were harvested by centrifugation at 6,000 ⫻ g for 10 min, suspended in 5 ml binding buffer (BB: 0.5 M
NaCl, 20 mM Tris-HCl, 5 mM imidazole [pH 7.9]), sonicated for 30 s, and collected by centrifugation. The
cell pellets were suspended in 5 ml BB containing 6 M urea and sonicated again. Following centrifugation, the supernatant was collected and centrifuged at 20,000 ⫻ g for 5 min to remove residual insoluble
material. Clariﬁed supernatants from two 50-ml cultures were combined (ca. 9 ml) and applied to a 3-ml
bed volume of His·bind resin that had been equilibrated with BB plus 6 M urea. The column was washed
with 15 ml BB– 6 M urea and 10 ml wash buffer (0.5 M NaCl, 20 mM Tris-HCl, 60 mM imidazole, 6 M urea
[pH 7.9]), and protein was eluted with a mixture of 0.5 M NaCl, 20 mM Tris-HCl, 1 M imidazole, and 6 M
urea (pH 7.9). The eluate was collected in 1-ml fractions, which were each analyzed by SDS-PAGE to
determine which fractions to pool—typically 3 to 4 fractions. The puriﬁed protein was dialyzed against
6 M urea–20 mM Tris-HCl and concentrated to 10 mg/ml using Amicon Ultra-15 centrifugal ﬁlters (10-kDA
cutoff; Merck Millipore, Cork, Ireland). All procedures following the growth of cells were at 22°C. Protein
determinations were by the bicinchoninic acid assay. Samples of concentrated protein were stored at
⫺80°C. For SDS-PAGE, proteins were separated on 4 to 20% gradient gels (BioRad) in Tris-glycine-SDS
running buffer and stained with Coomassie (Expedeon, Ltd., Cambridgeshire, United Kingdom); protein
standards were from BioRad.
GP vaccines. Saccharomyces cerevisiae cells were puriﬁed into GPs following a series of hot alkali,
organic, and aqueous extraction steps, as described previously (20, 21, 46, 47). The ﬁnal GP vaccine
consisted of recombinant protein, mouse serum albumin (MSA; Equitech-Bio, Kerrville, TX) and yeast RNA
(yRNA; Sigma-Aldrich, St. Louis, MO) complexed within the glucan shells. Each recombinant protein at
10 mg/ml in 6 M urea–20 mM Tris-HCl was loaded into GPs and complexed with MSA and yRNA as
described previously (20, 21, 46). Vaccines were diluted in sterile 0.9% saline for injection to deliver 10 g
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of antigen and 25 g of MSA complexed with yRNA in 200 g GPs (approximately 108 particles) per
0.1-ml dose. Control vaccine was prepared identically with GPs loaded with MSA and yRNA, but without
recombinant protein. Vaccines were stored in 0.6-ml aliquots at ⫺80°C and brieﬂy vortexed prior to use.
Vaccine formulations were quality controlled by manual counting of GPs per milliliter using a hemocytometer, microscopically assessing for intact GPs with a phase-distinct protein-yRNA complex. Vaccines
were also extracted and analyzed by 10% SDS-PAGE to verify loading of antigens and MSA (15).
Mice. Six-week-old female C57BL/6 and BALB/c mice were obtained from either Charles River
Laboratories, Inc. (Kingston, NY), or The Jackson Laboratory (Bar Harbor, ME). The Abb knockout/
transgenic HLA-DR4 (DR4) mice were from Taconic Biosciences (Hudson, NY). Mice were bred and housed
in a speciﬁc-pathogen-free environment in the animal facilities at the University of Massachusetts
Medical School. Vaccinations commenced when the mice were 6 to 10 weeks of age; both male and
female mice were used. All animal procedures were carried out under a protocol approved by the
University of Massachusetts Medical School Institutional Use and Care of Animals Committee.
Vaccination and challenge studies. The GP-based vaccines (0.1-ml dose) were administered three
times at 2-week intervals as a subcutaneous injection at the midline of the abdomen, as described
previously (20, 21). Two weeks following the third vaccination, the mice were challenged with 104 CFU
of C. neoformans strain KN99 or C. gattii strain R265 in 50 l of PBS. Mice were anesthetized with 2%
isoﬂurane (Piramal Health Care, Andrah Pradesh, India) in a VetEquip laboratory animal anesthesia system
(VetEquip, Livermore, CA) and inoculated orotracheally. For survival studies, mice were monitored twice
daily and euthanized if they developed advanced signs of disease, including ataxia, listlessness, and
failure to groom. At the termination of the study, the surviving mice were euthanized, and their lungs
and brains were removed. Lungs were weighed, and the organs were homogenized in PBS containing
100 U/ml penicillin and 100 g/ml streptomycin (lungs in 4 ml and brains in 2 ml) using an Omni TH
tissue homogenizer and plastic homogenizing probes (Omni, Kennesaw, GA). Undiluted and diluted
homogenates were plated on Sabouraud medium and incubated at 30°C for 2 to 3 days, at which time
fungal CFU were enumerated. In other studies, mice were euthanized at various times after fungal
challenge to enumerate CFU. The lower limit of detection was 20 CFU. Lungs with no CFU were arbitrarily
assigned a value of 20 CFU.
Histology. Lungs from euthanized mice were inﬂated with 0.5 ml 4% paraformaldehyde in PBS and
then excised. Following embedding in parafﬁn, 5-m sections obtained from each of ﬁve lobes were
mounted on glass slides and stained with H&E or mucicarmine (Sigma-Aldrich). A pathologist, blind as
to experimental group, then scored the slides on a scale of 0 to 3 for pulmonary inﬂammation and fungal
burden as shown in Fig. S2.
Immunoinformatics. Each of the six proteins was analyzed as previously described to evaluate the
distribution of B cell linear epitopes, MHC binding for human and murine alleles (48, 49), and the
presence or absence of possible suppressive T cell epitope motifs (50, 51). In addition, both wild-type and
recombinant sequences of each candidate protein were evaluated to determine the content of highfrequency T-cell-exposed motifs relative to all other proteins in the C. neoformans proteome (51). More
details are presented following the legend to Fig. S2.
Statistics. Data were analyzed using GraphPad Prism, version 6.0 (GraphPad Software, Inc., La Jolla,
CA). Kaplan-Meier survival curves were compared using the Mantel-Cox log rank test. The unpaired
two-tailed t test was used for comparisons of two groups with the Bonferroni correction applied for
multiple comparisons. The one-way analysis of variance (ANOVA) with the Tukey multiple-correction test
was used to compare more than two groups.
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